Novel astatine (211At)-labelled prostate-specific membrane antigen ligand with a neopentyl-glycol structure: evaluation of stability, efficacy, and safety using a prostate cancer xenograft model
[<sup>211</sup>At]At-NpG-PSMA demonstrated significant stability in vivo and anti-tumour effects with minimal side effects, indicating its potential as a new therapeutic drug for PSMA-targeted alpha therapy in mCRPC.
Authors
- Tomoki Yamashita (ORCID: https://orcid.org/0000-0003-2394-324X)
- Tomoya Uehara (ORCID: https://orcid.org/0000-0002-1140-9800)
- Syunta Makabe
- Kei Yaginuma
- Hiroyuki Suzuki (ORCID: https://orcid.org/0000-0002-9560-4274)
- Naoko Hasegawa (ORCID: https://orcid.org/0000-0003-1097-8232)
- Satoru Meguro (ORCID: https://orcid.org/0000-0003-2179-5028)
- Koki Hasegawa (ORCID: https://orcid.org/0000-0003-2145-3183)
- Soichiro Ogawa (ORCID: https://orcid.org/0000-0001-6002-7879)
- Akifumi Onagi (ORCID: https://orcid.org/0000-0002-4906-2558)
- Kanako Matsuoka (ORCID: https://orcid.org/0000-0002-0731-4577)
- Seiji Hoshi (ORCID: https://orcid.org/0000-0003-1545-1827)
- Naoyuki Ukon (ORCID: https://orcid.org/0000-0002-6715-582X)
- Taiki Joho
- Kazuhiro Takahashi (ORCID: https://orcid.org/0000-0001-8943-1875)
- Songji Zhao
- Yoshiyuki Kojima (ORCID: https://orcid.org/0000-0001-8000-0868)
- Motohide Uemura (ORCID: https://orcid.org/0000-0001-7263-7965)
- Saki Shimoyama
Institutions
- Fukushima Medical University (JP)
- Chiba University (JP)
Publication Details
- Journal
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1007/s00259-024-06945-x
- Citations
- 11
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.61
Funders
- Takeda Science Foundation
- Case Western Reserve University
- Kobayashi Foundation for Cancer Research